Research Article
Six-Year Real-World Outcomes of Antivascular Endothelial Growth Factor Monotherapy and Combination Therapy for Various Subtypes of Polypoidal Choroidal Vasculopathy
Table 3
Anatomical outcomes for 72 months in eyes with PCV by optical coherence tomography.
| |||||||||||||||||||||||||||||||||||||||
PCV, polypoidal choroidal vasculopathy; VEGF, vascular endothelial growth factor. |